Physicians' Academy for Cardiovascular Education

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands

How early do we see the CVD benefits of LDL-C lowering?

5' education - Oct. 31, 2018 - Philip Barter, MD - Sydney, Australia

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands

U-prevent predicts lifetime risk of CV events in healthy individuals

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Not all fish oils are created equal: different compounds have different effects

AHA 2018 – Chicago, IL, USA

3' education - Nov. 13, 2018 - Deepak Bhatt, MD
Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

Initiation of ARNI in patients with acute decompensated heart failure

AHA 2018 - Chicago, IL, USA

3' education - Nov. 13, 2018 - Eric Velazquez, MD
Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

AHA 2018 – Chicago, IL, USA

3' education - Nov. 12, 2018 - Jane Wilcox, MD
The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

AHA 2018 – Chicago, IL, VS

News - Nov. 12, 2018

AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.

Recovery after dilated cardiomyopathy often means remission rather than cure

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 The TRED-HF evaluated well monitored withdrawal of pharmacological HF therapy and found that about 40% of patients deemed to have recovered DCM showed relapse.

Cholesterol absorption inhibitor prevents atherosclerotic CV events in older patients

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.

U.S. Department of Health & Human Services releases physical activity guidelines for Americans, 2nd edition

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.

ARNI lowers NT-proBNP and rehospitalization for HF in stabilized acute decompensated HF

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 The results of the PIONEER-HF trial support the in-hospital initiation of sacubitril/valsartan in stabilized patients with acute decompensated heart failure and reduced EF.

Yoga-based cardiac rehabilitation post-MI improves quality of life, but not CV events

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.

Apo(a) antisense oligonucleotides safely and effectively reduces Lp(a) in patients with CVD

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018

AHA 2018 A randomized phase 2b trial showed safety and efficacy of the antisense nucleotide AKCEA-APO(a)-Lrx at reducing Lp(a) levels in patients with CVD.

Neither omega-3s, nor vitamin D, reduce major CVD events in primary prevention cohort

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018

AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

AHA 2018 - Chicago, IL, USA

3' education - Nov. 11, 2018
Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.